TCIM
RNAC icon

TIAA CREF Investment Management’s Cartesian Therapeutics RNAC Stock Holding History

TIAA CREF Investment Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$74K Hold
1,044
– – ﹤0.01% 2977
2018
Q4 		$83K Hold
1,044
– – ﹤0.01% 2975
2018
Q3 		$487K Sell
1,044
-65
-6% -$26.1K ﹤0.01% 2725
2018
Q2 		$441K Sell
1,109
-125
-10% -$44.3K ﹤0.01% 2843
2018
Q1 		$377K Buy
1,234
+122
+11% +$34.8K ﹤0.01% 2848
2017
Q4 		$327K Sell
1,112
-170
-13% -$74.3K ﹤0.01% 2925
2017
Q3 		$702K Sell
1,282
-112
-8% -$59.6K ﹤0.01% 2678
2017
Q2 		$830K Buy
1,394
+1,223
+715% +$540K ﹤0.01% 2635
2017
Q1 		$74K Buy
171
+12
+8% +$5.05K ﹤0.01% 3056
2016
Q4 		$82K Buy
+159
New +$92.9K ﹤0.01% 3092

Other funds holding RNAC

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA CREF Investment Management's RNAC Position: Q1 2019 in Review

TIAA CREF Investment Management held its Cartesian Therapeutics (RNAC) position steady in Q1 2019 at 1,044 shares worth $74K. The position accounts for ﹤0.01% of the portfolio, ranked #2977.

TIAA CREF Investment Management first reported a position in RNAC in Q4 2016 and has held it in 10 quarters since. The position peaked at $830K in Q2 2017. 56 funds tracked by Wall St. Rank hold RNAC as of Q1 2019.

  • TIAA CREF Investment Management held 1,044 shares of Cartesian Therapeutics worth $74K as of Q1 2019.
  • TIAA CREF Investment Management left its Cartesian Therapeutics share count unchanged in Q1 2019.
  • Cartesian Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2977 holding.
  • TIAA CREF Investment Management first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 10 quarters since.
  • TIAA CREF Investment Management's Cartesian Therapeutics position peaked at $830K in Q2 2017.
  • 56 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.